## Antibody-Drug Conjugates

## What are Antibody-Drug Conjugates?

Antibody-Drug Conjugates (ADCs) are the outcome of merging monoclonal antibodies with cytotoxic drugs using a linker. The monoclonal antibody selectively targets antigens overexpressed on cancer cells, ensuring precise payload delivery while sparing healthy tissues.

A fast-emerging class of therapeutic agents...


Clinical stage of current ADC under development
... however, they represent about 16\% of all the therapeutic antibodies currently under clinical development.

ADCs currently on the European market

Ovarian Cancer:
1 marketed ADC
58 under development

Breast Cancer:
2 marketed ADC
99 under development

Cervical Cancer:
1 marketed ADC
17 under development

Leukaemia:
2 marketed ADC
21 under development

Urothelial cancer:
1 marketed ADC
23 under development

Lymphoma:
1 marketed ADC
37 under development

Triple-Negative Breast Cancer:
1 marketed ADC
39 under development


$\oplus$

Diffuse Large B-Cell Lymphoma:
1 marketed ADC
14 under development

